Detailed description page of THPdb

This page displays user query in tabular form.

Th1132 details

Primary information
ID 1609
ThPP ID Th1132
Therapeutic Peptide/Protein Name Belimumab
Sequence N.A. view full sequnce in fasta
Functional Classification IIa
Molecular Weight 147000
Chemical Formula C 6358 H 9904 N 1728 O 2010 S 44
Isoelectric Point N.A.
Hydrophobicity N.A.
Melting Point (℃) N.A.
Half Life Elimination half life- 19.4 days, Distribution half life- 1.75 days
Description RAV12 is a monoclonal antibody that is being studied in the treatment of certain cancers.It binds to a carbohydrate molecule found on gastric, colon, pancreatic, prostate, ovarian, breast, and kidney cancer cells. Administering RAV12 along with gemcitabine may kill more tumor cells than either one alone.
Indication/Disease Adjunct treatment for auto-antibody-positive active systemic lupus erythematosus.
Pharmacodynamics By the 52nd week of treatment with belimumab, a reduction in CD19+, CD20+, naive and activated B cells, plasma cells, plasmacytoid cells, and SLE B-cell subset can be observed. Reductions in plasma cells and SLE B-cell subset can be seen by the eighth week and these levels were maintained to week 52. Belimumab also reduced levels of IgG and anti-dsDNA.
Mechanism of Action Belimumab selectively binds to soluble human B lymphocyte stimulator protein (BLyS) so that BLyS is unable to bind to receptors on B lymphocytes. The binding of BLyS to its receptor is essential for the survival of B lymphocytes. Consequently, belimumab reduces B-cell mediated immunity and the autoimmune response.
Toxicity The most commonly-reported adverse reactions, occurring in â‰¥ 5% of patients in clinical trials were nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis. The most common serious adverse reactions were serious infections.
Metabolism Because belimumab is a protein, it is expected that it is degraded into peptides and amino acids by proteolytic enzymes.
Absorption Cmax, 10 mg/kg, SLE patients = 313 Âµg/mL; AUC (0 - âˆž), 10 mg/kg, SLE patients = 3083.
Volume of Distribution Vdss, 10 mg/kg, SLE patients = 5.29 L.
Clearance Systemic clearance, 10 mg/kg, SLE patients = 215 mL/day.
Categories Monoclonal antibodies
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target Tumor necrosis factor ligand superfamily member 13B
Information of corresponding available drug in the market
Brand Name Benlysta
Company GlaxoSmithKline
Brand Discription BENLYSTA (belimumab) is a human IgG1Î» monoclonal antibody specific for soluble human B lymphocyte stimulator protein (BLyS, also referred to as BAFF and TNFSF13B). Belimumab has a molecular weight of approximately 147 kDa. Belimumab is produced by recombinant DNA technology in a mammalian cell expression system.
Prescribed for N.A.
Chemical Name N.A.
Formulation Upon reconstitution with Sterile Water for Injection, USP, each single-use vial delivers 80 mg/mL belimumab in 0.16 mg/mL citric acid, 0.4 mg/mL polysorbate 80, 2.7 mg/mL sodium citrate, and 80 mg/mL sucrose, with a pH of 6.5.
Physcial Appearance BENLYSTA is supplied as a sterile, white to off-white, preservative-free, lyophilized powder for Intravenous infusion
Route of Administration Intravenous infusion
Recommended Dosage 10 mg/kg at 2-week intervals for the first 3 doses and at 4-week intervals thereafter. Reconstitute, dilute, and administer as an Intravenous infusion only, over a period of 1 hour.
Contraindication anaphylaxis with belimumab
Side Effects Mortality, Serious Infections, Malignancy, Hypersensitivity Reactions, Including Anaphylaxis, Infusion Reactions, Depression
Useful Link http://www.rxlist.com/benlysta-drug.htm http://www.benlysta.com/ http://en.wikipedia.org/wiki/Belimumab
PubMed ID 25652332, 25609919, 25543845, 22428610
3-D Structure N.A.

Primary information
ID 1610
ThPP ID Th1132
Therapeutic Peptide/Protein Name Belimumab
Sequence N.A. view full sequnce in fasta
Functional Classification IIa
Molecular Weight 147000
Chemical Formula C 6358 H 9904 N 1728 O 2010 S 44
Isoelectric Point N.A.
Hydrophobicity N.A.
Melting Point (℃) N.A.
Half Life Elimination half life- 19.4 days, Distribution half life- 1.75 days
Description RAV12 is a monoclonal antibody that is being studied in the treatment of certain cancers.It binds to a carbohydrate molecule found on gastric, colon, pancreatic, prostate, ovarian, breast, and kidney cancer cells. Administering RAV12 along with gemcitabine may kill more tumor cells than either one alone.
Indication/Disease Adjunct treatment for auto-antibody-positive active systemic lupus erythematosus.
Pharmacodynamics By the 52nd week of treatment with belimumab, a reduction in CD19+, CD20+, naive and activated B cells, plasma cells, plasmacytoid cells, and SLE B-cell subset can be observed. Reductions in plasma cells and SLE B-cell subset can be seen by the eighth week and these levels were maintained to week 52. Belimumab also reduced levels of IgG and anti-dsDNA.
Mechanism of Action Belimumab selectively binds to soluble human B lymphocyte stimulator protein (BLyS) so that BLyS is unable to bind to receptors on B lymphocytes. The binding of BLyS to its receptor is essential for the survival of B lymphocytes. Consequently, belimumab reduces B-cell mediated immunity and the autoimmune response.
Toxicity The most commonly-reported adverse reactions, occurring in â‰¥ 5% of patients in clinical trials were nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis. The most common serious adverse reactions were serious infections.
Metabolism Because belimumab is a protein, it is expected that it is degraded into peptides and amino acids by proteolytic enzymes.
Absorption Cmax, 10 mg/kg, SLE patients = 313 Âµg/mL; AUC (0 - âˆž), 10 mg/kg, SLE patients = 3083.
Volume of Distribution Vdss, 10 mg/kg, SLE patients = 5.29 L.
Clearance Systemic clearance, 10 mg/kg, SLE patients = 215 mL/day.
Categories Monoclonal antibodies
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target N.A.
Information of corresponding available drug in the market
Brand Name N.A.
Company N.A.
Brand Discription N.A.
Prescribed for N.A.
Chemical Name N.A.
Formulation N.A.
Physcial Appearance N.A.
Route of Administration N.A.
Recommended Dosage N.A.
Contraindication N.A.
Side Effects N.A.
Useful Link N.A.
PubMed ID 25652332, 25609919, 25543845, 22428610
3-D Structure N.A.

Primary information
ID 1611
ThPP ID Th1132
Therapeutic Peptide/Protein Name Belimumab
Sequence N.A. view full sequnce in fasta
Functional Classification IIa
Molecular Weight 147000
Chemical Formula C 6358 H 9904 N 1728 O 2010 S 44
Isoelectric Point N.A.
Hydrophobicity N.A.
Melting Point (℃) N.A.
Half Life Elimination half life- 19.4 days, Distribution half life- 1.75 days
Description RAV12 is a monoclonal antibody that is being studied in the treatment of certain cancers.It binds to a carbohydrate molecule found on gastric, colon, pancreatic, prostate, ovarian, breast, and kidney cancer cells. Administering RAV12 along with gemcitabine may kill more tumor cells than either one alone.
Indication/Disease Adjunct treatment for auto-antibody-positive active systemic lupus erythematosus.
Pharmacodynamics By the 52nd week of treatment with belimumab, a reduction in CD19+, CD20+, naive and activated B cells, plasma cells, plasmacytoid cells, and SLE B-cell subset can be observed. Reductions in plasma cells and SLE B-cell subset can be seen by the eighth week and these levels were maintained to week 52. Belimumab also reduced levels of IgG and anti-dsDNA.
Mechanism of Action Belimumab selectively binds to soluble human B lymphocyte stimulator protein (BLyS) so that BLyS is unable to bind to receptors on B lymphocytes. The binding of BLyS to its receptor is essential for the survival of B lymphocytes. Consequently, belimumab reduces B-cell mediated immunity and the autoimmune response.
Toxicity The most commonly-reported adverse reactions, occurring in â‰¥ 5% of patients in clinical trials were nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis. The most common serious adverse reactions were serious infections.
Metabolism Because belimumab is a protein, it is expected that it is degraded into peptides and amino acids by proteolytic enzymes.
Absorption Cmax, 10 mg/kg, SLE patients = 313 Âµg/mL; AUC (0 - âˆž), 10 mg/kg, SLE patients = 3083.
Volume of Distribution Vdss, 10 mg/kg, SLE patients = 5.29 L.
Clearance Systemic clearance, 10 mg/kg, SLE patients = 215 mL/day.
Categories Monoclonal antibodies
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target N.A.
Information of corresponding available drug in the market
Brand Name N.A.
Company N.A.
Brand Discription N.A.
Prescribed for N.A.
Chemical Name N.A.
Formulation N.A.
Physcial Appearance N.A.
Route of Administration N.A.
Recommended Dosage N.A.
Contraindication N.A.
Side Effects N.A.
Useful Link N.A.
PubMed ID 25652332, 25609919, 25543845, 22428610
3-D Structure N.A.

Primary information
ID 1612
ThPP ID Th1132
Therapeutic Peptide/Protein Name Belimumab
Sequence N.A. view full sequnce in fasta
Functional Classification IIa
Molecular Weight 147000
Chemical Formula C 6358 H 9904 N 1728 O 2010 S 44
Isoelectric Point N.A.
Hydrophobicity N.A.
Melting Point (℃) N.A.
Half Life Elimination half life- 19.4 days, Distribution half life- 1.75 days
Description RAV12 is a monoclonal antibody that is being studied in the treatment of certain cancers.It binds to a carbohydrate molecule found on gastric, colon, pancreatic, prostate, ovarian, breast, and kidney cancer cells. Administering RAV12 along with gemcitabine may kill more tumor cells than either one alone.
Indication/Disease Adjunct treatment for auto-antibody-positive active systemic lupus erythematosus.
Pharmacodynamics By the 52nd week of treatment with belimumab, a reduction in CD19+, CD20+, naive and activated B cells, plasma cells, plasmacytoid cells, and SLE B-cell subset can be observed. Reductions in plasma cells and SLE B-cell subset can be seen by the eighth week and these levels were maintained to week 52. Belimumab also reduced levels of IgG and anti-dsDNA.
Mechanism of Action Belimumab selectively binds to soluble human B lymphocyte stimulator protein (BLyS) so that BLyS is unable to bind to receptors on B lymphocytes. The binding of BLyS to its receptor is essential for the survival of B lymphocytes. Consequently, belimumab reduces B-cell mediated immunity and the autoimmune response.
Toxicity The most commonly-reported adverse reactions, occurring in â‰¥ 5% of patients in clinical trials were nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis. The most common serious adverse reactions were serious infections.
Metabolism Because belimumab is a protein, it is expected that it is degraded into peptides and amino acids by proteolytic enzymes.
Absorption Cmax, 10 mg/kg, SLE patients = 313 Âµg/mL; AUC (0 - âˆž), 10 mg/kg, SLE patients = 3083.
Volume of Distribution Vdss, 10 mg/kg, SLE patients = 5.29 L.
Clearance Systemic clearance, 10 mg/kg, SLE patients = 215 mL/day.
Categories Monoclonal antibodies
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target N.A.
Information of corresponding available drug in the market
Brand Name N.A.
Company N.A.
Brand Discription N.A.
Prescribed for N.A.
Chemical Name N.A.
Formulation N.A.
Physcial Appearance N.A.
Route of Administration N.A.
Recommended Dosage N.A.
Contraindication N.A.
Side Effects N.A.
Useful Link N.A.
PubMed ID 25652332, 25609919, 25543845, 22428610
3-D Structure N.A.

Primary information
ID 1613
ThPP ID Th1132
Therapeutic Peptide/Protein Name Belimumab
Sequence N.A. view full sequnce in fasta
Functional Classification IIa
Molecular Weight 147000
Chemical Formula C 6358 H 9904 N 1728 O 2010 S 44
Isoelectric Point N.A.
Hydrophobicity N.A.
Melting Point (℃) N.A.
Half Life Elimination half life- 19.4 days, Distribution half life- 1.75 days
Description RAV12 is a monoclonal antibody that is being studied in the treatment of certain cancers.It binds to a carbohydrate molecule found on gastric, colon, pancreatic, prostate, ovarian, breast, and kidney cancer cells. Administering RAV12 along with gemcitabine may kill more tumor cells than either one alone.
Indication/Disease Adjunct treatment for auto-antibody-positive active systemic lupus erythematosus.
Pharmacodynamics By the 52nd week of treatment with belimumab, a reduction in CD19+, CD20+, naive and activated B cells, plasma cells, plasmacytoid cells, and SLE B-cell subset can be observed. Reductions in plasma cells and SLE B-cell subset can be seen by the eighth week and these levels were maintained to week 52. Belimumab also reduced levels of IgG and anti-dsDNA.
Mechanism of Action Belimumab selectively binds to soluble human B lymphocyte stimulator protein (BLyS) so that BLyS is unable to bind to receptors on B lymphocytes. The binding of BLyS to its receptor is essential for the survival of B lymphocytes. Consequently, belimumab reduces B-cell mediated immunity and the autoimmune response.
Toxicity The most commonly-reported adverse reactions, occurring in â‰¥ 5% of patients in clinical trials were nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis. The most common serious adverse reactions were serious infections.
Metabolism Because belimumab is a protein, it is expected that it is degraded into peptides and amino acids by proteolytic enzymes.
Absorption Cmax, 10 mg/kg, SLE patients = 313 Âµg/mL; AUC (0 - âˆž), 10 mg/kg, SLE patients = 3083.
Volume of Distribution Vdss, 10 mg/kg, SLE patients = 5.29 L.
Clearance Systemic clearance, 10 mg/kg, SLE patients = 215 mL/day.
Categories Monoclonal antibodies
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target N.A.
Information of corresponding available drug in the market
Brand Name N.A.
Company N.A.
Brand Discription N.A.
Prescribed for N.A.
Chemical Name N.A.
Formulation N.A.
Physcial Appearance N.A.
Route of Administration N.A.
Recommended Dosage N.A.
Contraindication N.A.
Side Effects N.A.
Useful Link N.A.
PubMed ID 25652332, 25609919, 25543845, 22428610
3-D Structure N.A.

Primary information
ID 1614
ThPP ID Th1132
Therapeutic Peptide/Protein Name Belimumab
Sequence N.A. view full sequnce in fasta
Functional Classification IIa
Molecular Weight 147000
Chemical Formula C 6358 H 9904 N 1728 O 2010 S 44
Isoelectric Point N.A.
Hydrophobicity N.A.
Melting Point (℃) N.A.
Half Life Elimination half life- 19.4 days, Distribution half life- 1.75 days
Description RAV12 is a monoclonal antibody that is being studied in the treatment of certain cancers.It binds to a carbohydrate molecule found on gastric, colon, pancreatic, prostate, ovarian, breast, and kidney cancer cells. Administering RAV12 along with gemcitabine may kill more tumor cells than either one alone.
Indication/Disease Adjunct treatment for auto-antibody-positive active systemic lupus erythematosus.
Pharmacodynamics By the 52nd week of treatment with belimumab, a reduction in CD19+, CD20+, naive and activated B cells, plasma cells, plasmacytoid cells, and SLE B-cell subset can be observed. Reductions in plasma cells and SLE B-cell subset can be seen by the eighth week and these levels were maintained to week 52. Belimumab also reduced levels of IgG and anti-dsDNA.
Mechanism of Action Belimumab selectively binds to soluble human B lymphocyte stimulator protein (BLyS) so that BLyS is unable to bind to receptors on B lymphocytes. The binding of BLyS to its receptor is essential for the survival of B lymphocytes. Consequently, belimumab reduces B-cell mediated immunity and the autoimmune response.
Toxicity The most commonly-reported adverse reactions, occurring in â‰¥ 5% of patients in clinical trials were nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis. The most common serious adverse reactions were serious infections.
Metabolism Because belimumab is a protein, it is expected that it is degraded into peptides and amino acids by proteolytic enzymes.
Absorption Cmax, 10 mg/kg, SLE patients = 313 Âµg/mL; AUC (0 - âˆž), 10 mg/kg, SLE patients = 3083.
Volume of Distribution Vdss, 10 mg/kg, SLE patients = 5.29 L.
Clearance Systemic clearance, 10 mg/kg, SLE patients = 215 mL/day.
Categories Monoclonal antibodies
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target N.A.
Information of corresponding available drug in the market
Brand Name N.A.
Company N.A.
Brand Discription N.A.
Prescribed for N.A.
Chemical Name N.A.
Formulation N.A.
Physcial Appearance N.A.
Route of Administration N.A.
Recommended Dosage N.A.
Contraindication N.A.
Side Effects N.A.
Useful Link N.A.
PubMed ID 25652332, 25609919, 25543845, 22428610
3-D Structure N.A.

OSDDlinux

Raghava's Group

IMTECH

CSIR

CRDD
CPPSITE 2.0

Primary information
ID	1609
ThPP ID	Th1132
Therapeutic Peptide/Protein Name	Belimumab
Sequence	N.A. view full sequnce in fasta
Functional Classification	IIa
Molecular Weight	147000
Chemical Formula	C 6358 H 9904 N 1728 O 2010 S 44
Isoelectric Point	N.A.
Hydrophobicity	N.A.
Melting Point (℃)	N.A.
Half Life	Elimination half life- 19.4 days, Distribution half life- 1.75 days
Description	RAV12 is a monoclonal antibody that is being studied in the treatment of certain cancers.It binds to a carbohydrate molecule found on gastric, colon, pancreatic, prostate, ovarian, breast, and kidney cancer cells. Administering RAV12 along with gemcitabine may kill more tumor cells than either one alone.
Indication/Disease	Adjunct treatment for auto-antibody-positive active systemic lupus erythematosus.
Pharmacodynamics	By the 52nd week of treatment with belimumab, a reduction in CD19+, CD20+, naive and activated B cells, plasma cells, plasmacytoid cells, and SLE B-cell subset can be observed. Reductions in plasma cells and SLE B-cell subset can be seen by the eighth week and these levels were maintained to week 52. Belimumab also reduced levels of IgG and anti-dsDNA.
Mechanism of Action	Belimumab selectively binds to soluble human B lymphocyte stimulator protein (BLyS) so that BLyS is unable to bind to receptors on B lymphocytes. The binding of BLyS to its receptor is essential for the survival of B lymphocytes. Consequently, belimumab reduces B-cell mediated immunity and the autoimmune response.
Toxicity	The most commonly-reported adverse reactions, occurring in â‰¥ 5% of patients in clinical trials were nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis. The most common serious adverse reactions were serious infections.
Metabolism	Because belimumab is a protein, it is expected that it is degraded into peptides and amino acids by proteolytic enzymes.
Absorption	Cmax, 10 mg/kg, SLE patients = 313 Âµg/mL; AUC (0 - âˆž), 10 mg/kg, SLE patients = 3083.
Volume of Distribution	Vdss, 10 mg/kg, SLE patients = 5.29 L.
Clearance	Systemic clearance, 10 mg/kg, SLE patients = 215 mL/day.
Categories	Monoclonal antibodies
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	Tumor necrosis factor ligand superfamily member 13B
Information of corresponding available drug in the market
Brand Name	Benlysta
Company	GlaxoSmithKline
Brand Discription	BENLYSTA (belimumab) is a human IgG1Î» monoclonal antibody specific for soluble human B lymphocyte stimulator protein (BLyS, also referred to as BAFF and TNFSF13B). Belimumab has a molecular weight of approximately 147 kDa. Belimumab is produced by recombinant DNA technology in a mammalian cell expression system.
Prescribed for	N.A.
Chemical Name	N.A.
Formulation	Upon reconstitution with Sterile Water for Injection, USP, each single-use vial delivers 80 mg/mL belimumab in 0.16 mg/mL citric acid, 0.4 mg/mL polysorbate 80, 2.7 mg/mL sodium citrate, and 80 mg/mL sucrose, with a pH of 6.5.
Physcial Appearance	BENLYSTA is supplied as a sterile, white to off-white, preservative-free, lyophilized powder for Intravenous infusion
Route of Administration	Intravenous infusion
Recommended Dosage	10 mg/kg at 2-week intervals for the first 3 doses and at 4-week intervals thereafter. Reconstitute, dilute, and administer as an Intravenous infusion only, over a period of 1 hour.
Contraindication	anaphylaxis with belimumab
Side Effects	Mortality, Serious Infections, Malignancy, Hypersensitivity Reactions, Including Anaphylaxis, Infusion Reactions, Depression
Useful Link	http://www.rxlist.com/benlysta-drug.htm http://www.benlysta.com/ http://en.wikipedia.org/wiki/Belimumab
PubMed ID	25652332, 25609919, 25543845, 22428610
3-D Structure	N.A.

Primary information
ID	1610
ThPP ID	Th1132
Therapeutic Peptide/Protein Name	Belimumab
Sequence	N.A. view full sequnce in fasta
Functional Classification	IIa
Molecular Weight	147000
Chemical Formula	C 6358 H 9904 N 1728 O 2010 S 44
Isoelectric Point	N.A.
Hydrophobicity	N.A.
Melting Point (℃)	N.A.
Half Life	Elimination half life- 19.4 days, Distribution half life- 1.75 days
Description	RAV12 is a monoclonal antibody that is being studied in the treatment of certain cancers.It binds to a carbohydrate molecule found on gastric, colon, pancreatic, prostate, ovarian, breast, and kidney cancer cells. Administering RAV12 along with gemcitabine may kill more tumor cells than either one alone.
Indication/Disease	Adjunct treatment for auto-antibody-positive active systemic lupus erythematosus.
Pharmacodynamics	By the 52nd week of treatment with belimumab, a reduction in CD19+, CD20+, naive and activated B cells, plasma cells, plasmacytoid cells, and SLE B-cell subset can be observed. Reductions in plasma cells and SLE B-cell subset can be seen by the eighth week and these levels were maintained to week 52. Belimumab also reduced levels of IgG and anti-dsDNA.
Mechanism of Action	Belimumab selectively binds to soluble human B lymphocyte stimulator protein (BLyS) so that BLyS is unable to bind to receptors on B lymphocytes. The binding of BLyS to its receptor is essential for the survival of B lymphocytes. Consequently, belimumab reduces B-cell mediated immunity and the autoimmune response.
Toxicity	The most commonly-reported adverse reactions, occurring in â‰¥ 5% of patients in clinical trials were nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis. The most common serious adverse reactions were serious infections.
Metabolism	Because belimumab is a protein, it is expected that it is degraded into peptides and amino acids by proteolytic enzymes.
Absorption	Cmax, 10 mg/kg, SLE patients = 313 Âµg/mL; AUC (0 - âˆž), 10 mg/kg, SLE patients = 3083.
Volume of Distribution	Vdss, 10 mg/kg, SLE patients = 5.29 L.
Clearance	Systemic clearance, 10 mg/kg, SLE patients = 215 mL/day.
Categories	Monoclonal antibodies
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	N.A.
Information of corresponding available drug in the market
Brand Name	N.A.
Company	N.A.
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	N.A.
Formulation	N.A.
Physcial Appearance	N.A.
Route of Administration	N.A.
Recommended Dosage	N.A.
Contraindication	N.A.
Side Effects	N.A.
Useful Link	N.A.
PubMed ID	25652332, 25609919, 25543845, 22428610
3-D Structure	N.A.

Primary information
ID	1611
ThPP ID	Th1132
Therapeutic Peptide/Protein Name	Belimumab
Sequence	N.A. view full sequnce in fasta
Functional Classification	IIa
Molecular Weight	147000
Chemical Formula	C 6358 H 9904 N 1728 O 2010 S 44
Isoelectric Point	N.A.
Hydrophobicity	N.A.
Melting Point (℃)	N.A.
Half Life	Elimination half life- 19.4 days, Distribution half life- 1.75 days
Description	RAV12 is a monoclonal antibody that is being studied in the treatment of certain cancers.It binds to a carbohydrate molecule found on gastric, colon, pancreatic, prostate, ovarian, breast, and kidney cancer cells. Administering RAV12 along with gemcitabine may kill more tumor cells than either one alone.
Indication/Disease	Adjunct treatment for auto-antibody-positive active systemic lupus erythematosus.
Pharmacodynamics	By the 52nd week of treatment with belimumab, a reduction in CD19+, CD20+, naive and activated B cells, plasma cells, plasmacytoid cells, and SLE B-cell subset can be observed. Reductions in plasma cells and SLE B-cell subset can be seen by the eighth week and these levels were maintained to week 52. Belimumab also reduced levels of IgG and anti-dsDNA.
Mechanism of Action	Belimumab selectively binds to soluble human B lymphocyte stimulator protein (BLyS) so that BLyS is unable to bind to receptors on B lymphocytes. The binding of BLyS to its receptor is essential for the survival of B lymphocytes. Consequently, belimumab reduces B-cell mediated immunity and the autoimmune response.
Toxicity	The most commonly-reported adverse reactions, occurring in â‰¥ 5% of patients in clinical trials were nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis. The most common serious adverse reactions were serious infections.
Metabolism	Because belimumab is a protein, it is expected that it is degraded into peptides and amino acids by proteolytic enzymes.
Absorption	Cmax, 10 mg/kg, SLE patients = 313 Âµg/mL; AUC (0 - âˆž), 10 mg/kg, SLE patients = 3083.
Volume of Distribution	Vdss, 10 mg/kg, SLE patients = 5.29 L.
Clearance	Systemic clearance, 10 mg/kg, SLE patients = 215 mL/day.
Categories	Monoclonal antibodies
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	N.A.
Information of corresponding available drug in the market
Brand Name	N.A.
Company	N.A.
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	N.A.
Formulation	N.A.
Physcial Appearance	N.A.
Route of Administration	N.A.
Recommended Dosage	N.A.
Contraindication	N.A.
Side Effects	N.A.
Useful Link	N.A.
PubMed ID	25652332, 25609919, 25543845, 22428610
3-D Structure	N.A.

Primary information
ID	1612
ThPP ID	Th1132
Therapeutic Peptide/Protein Name	Belimumab
Sequence	N.A. view full sequnce in fasta
Functional Classification	IIa
Molecular Weight	147000
Chemical Formula	C 6358 H 9904 N 1728 O 2010 S 44
Isoelectric Point	N.A.
Hydrophobicity	N.A.
Melting Point (℃)	N.A.
Half Life	Elimination half life- 19.4 days, Distribution half life- 1.75 days
Description	RAV12 is a monoclonal antibody that is being studied in the treatment of certain cancers.It binds to a carbohydrate molecule found on gastric, colon, pancreatic, prostate, ovarian, breast, and kidney cancer cells. Administering RAV12 along with gemcitabine may kill more tumor cells than either one alone.
Indication/Disease	Adjunct treatment for auto-antibody-positive active systemic lupus erythematosus.
Pharmacodynamics	By the 52nd week of treatment with belimumab, a reduction in CD19+, CD20+, naive and activated B cells, plasma cells, plasmacytoid cells, and SLE B-cell subset can be observed. Reductions in plasma cells and SLE B-cell subset can be seen by the eighth week and these levels were maintained to week 52. Belimumab also reduced levels of IgG and anti-dsDNA.
Mechanism of Action	Belimumab selectively binds to soluble human B lymphocyte stimulator protein (BLyS) so that BLyS is unable to bind to receptors on B lymphocytes. The binding of BLyS to its receptor is essential for the survival of B lymphocytes. Consequently, belimumab reduces B-cell mediated immunity and the autoimmune response.
Toxicity	The most commonly-reported adverse reactions, occurring in â‰¥ 5% of patients in clinical trials were nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis. The most common serious adverse reactions were serious infections.
Metabolism	Because belimumab is a protein, it is expected that it is degraded into peptides and amino acids by proteolytic enzymes.
Absorption	Cmax, 10 mg/kg, SLE patients = 313 Âµg/mL; AUC (0 - âˆž), 10 mg/kg, SLE patients = 3083.
Volume of Distribution	Vdss, 10 mg/kg, SLE patients = 5.29 L.
Clearance	Systemic clearance, 10 mg/kg, SLE patients = 215 mL/day.
Categories	Monoclonal antibodies
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	N.A.
Information of corresponding available drug in the market
Brand Name	N.A.
Company	N.A.
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	N.A.
Formulation	N.A.
Physcial Appearance	N.A.
Route of Administration	N.A.
Recommended Dosage	N.A.
Contraindication	N.A.
Side Effects	N.A.
Useful Link	N.A.
PubMed ID	25652332, 25609919, 25543845, 22428610
3-D Structure	N.A.

Primary information
ID	1613
ThPP ID	Th1132
Therapeutic Peptide/Protein Name	Belimumab
Sequence	N.A. view full sequnce in fasta
Functional Classification	IIa
Molecular Weight	147000
Chemical Formula	C 6358 H 9904 N 1728 O 2010 S 44
Isoelectric Point	N.A.
Hydrophobicity	N.A.
Melting Point (℃)	N.A.
Half Life	Elimination half life- 19.4 days, Distribution half life- 1.75 days
Description	RAV12 is a monoclonal antibody that is being studied in the treatment of certain cancers.It binds to a carbohydrate molecule found on gastric, colon, pancreatic, prostate, ovarian, breast, and kidney cancer cells. Administering RAV12 along with gemcitabine may kill more tumor cells than either one alone.
Indication/Disease	Adjunct treatment for auto-antibody-positive active systemic lupus erythematosus.
Pharmacodynamics	By the 52nd week of treatment with belimumab, a reduction in CD19+, CD20+, naive and activated B cells, plasma cells, plasmacytoid cells, and SLE B-cell subset can be observed. Reductions in plasma cells and SLE B-cell subset can be seen by the eighth week and these levels were maintained to week 52. Belimumab also reduced levels of IgG and anti-dsDNA.
Mechanism of Action	Belimumab selectively binds to soluble human B lymphocyte stimulator protein (BLyS) so that BLyS is unable to bind to receptors on B lymphocytes. The binding of BLyS to its receptor is essential for the survival of B lymphocytes. Consequently, belimumab reduces B-cell mediated immunity and the autoimmune response.
Toxicity	The most commonly-reported adverse reactions, occurring in â‰¥ 5% of patients in clinical trials were nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis. The most common serious adverse reactions were serious infections.
Metabolism	Because belimumab is a protein, it is expected that it is degraded into peptides and amino acids by proteolytic enzymes.
Absorption	Cmax, 10 mg/kg, SLE patients = 313 Âµg/mL; AUC (0 - âˆž), 10 mg/kg, SLE patients = 3083.
Volume of Distribution	Vdss, 10 mg/kg, SLE patients = 5.29 L.
Clearance	Systemic clearance, 10 mg/kg, SLE patients = 215 mL/day.
Categories	Monoclonal antibodies
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	N.A.
Information of corresponding available drug in the market
Brand Name	N.A.
Company	N.A.
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	N.A.
Formulation	N.A.
Physcial Appearance	N.A.
Route of Administration	N.A.
Recommended Dosage	N.A.
Contraindication	N.A.
Side Effects	N.A.
Useful Link	N.A.
PubMed ID	25652332, 25609919, 25543845, 22428610
3-D Structure	N.A.

Primary information
ID	1614
ThPP ID	Th1132
Therapeutic Peptide/Protein Name	Belimumab
Sequence	N.A. view full sequnce in fasta
Functional Classification	IIa
Molecular Weight	147000
Chemical Formula	C 6358 H 9904 N 1728 O 2010 S 44
Isoelectric Point	N.A.
Hydrophobicity	N.A.
Melting Point (℃)	N.A.
Half Life	Elimination half life- 19.4 days, Distribution half life- 1.75 days
Description	RAV12 is a monoclonal antibody that is being studied in the treatment of certain cancers.It binds to a carbohydrate molecule found on gastric, colon, pancreatic, prostate, ovarian, breast, and kidney cancer cells. Administering RAV12 along with gemcitabine may kill more tumor cells than either one alone.
Indication/Disease	Adjunct treatment for auto-antibody-positive active systemic lupus erythematosus.
Pharmacodynamics	By the 52nd week of treatment with belimumab, a reduction in CD19+, CD20+, naive and activated B cells, plasma cells, plasmacytoid cells, and SLE B-cell subset can be observed. Reductions in plasma cells and SLE B-cell subset can be seen by the eighth week and these levels were maintained to week 52. Belimumab also reduced levels of IgG and anti-dsDNA.
Mechanism of Action	Belimumab selectively binds to soluble human B lymphocyte stimulator protein (BLyS) so that BLyS is unable to bind to receptors on B lymphocytes. The binding of BLyS to its receptor is essential for the survival of B lymphocytes. Consequently, belimumab reduces B-cell mediated immunity and the autoimmune response.
Toxicity	The most commonly-reported adverse reactions, occurring in â‰¥ 5% of patients in clinical trials were nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis. The most common serious adverse reactions were serious infections.
Metabolism	Because belimumab is a protein, it is expected that it is degraded into peptides and amino acids by proteolytic enzymes.
Absorption	Cmax, 10 mg/kg, SLE patients = 313 Âµg/mL; AUC (0 - âˆž), 10 mg/kg, SLE patients = 3083.
Volume of Distribution	Vdss, 10 mg/kg, SLE patients = 5.29 L.
Clearance	Systemic clearance, 10 mg/kg, SLE patients = 215 mL/day.
Categories	Monoclonal antibodies
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	N.A.
Information of corresponding available drug in the market
Brand Name	N.A.
Company	N.A.
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	N.A.
Formulation	N.A.
Physcial Appearance	N.A.
Route of Administration	N.A.
Recommended Dosage	N.A.
Contraindication	N.A.
Side Effects	N.A.
Useful Link	N.A.
PubMed ID	25652332, 25609919, 25543845, 22428610
3-D Structure	N.A.

Updated version of this database is available at ThpDB2

Detailed description page of THPdb